Pfizer CEO Sees Growth Beyond Patent Cliff, Highlights Monthly Obesity Drug Ambitions

Pfizer logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Pfizer expects a return to high single-digit growth after its patent-expiration period, which CEO Albert Bourla says should last about two more years. Recent launches grew 32% last quarter and represent roughly $15 billion to $16 billion in annualized revenue.
  • Pfizer is pursuing a monthly obesity treatment, citing consumer preference over weekly dosing and confidence in achieving comparable efficacy and tolerability, pending clinical results. A study will also test whether patients can maintain weight loss after switching from weekly treatments.
  • The company is advancing oncology and inflammation programs, including prostate cancer candidate mevrometostat and a trispecific atopic dermatitis treatment, while targeting $7.2 billion in net savings by year-end and announcing a further $1.5 billion in savings.
  • Five stocks to consider instead of Pfizer.

Pfizer NYSE: PFE expects recently launched medicines and a growing pipeline to help it emerge from a period of patent expirations with high single-digit growth, CEO Albert Bourla said at the Jefferies London Healthcare Conference.

Bourla said the loss-of-exclusivity period is expected to last another two years. Pfizer invested $80 billion in acquisitions after the COVID-19 pandemic to support new product launches and build its pipeline, he said.

The company’s launch products grew 32% in the latest quarter and represent approximately $15 billion to $16 billion in annualized revenue, according to Bourla. He also said Pfizer started 20 Phase 3 studies this year, nearly twice the number started the year before.

Pipeline and obesity ambitions

Bourla argued that analysts are underestimating both new launches and pipeline assets, including Pfizer’s obesity portfolio and cancer treatments targeting CDK4 and PD-1/VEGF. He said clinical trial results could narrow the gap between the company’s expectations and analysts’ forecasts.

In obesity, Bourla said Pfizer’s market research shows a strong consumer preference for monthly treatment over weekly alternatives. He said the company is confident it can achieve comparable efficacy and tolerability with a monthly product, though studies must confirm that profile.

Pfizer is also running a switch study to test whether patients who have reached a weight-loss plateau on weekly treatments can maintain their weight after moving to a monthly product, Bourla said. He pointed to Pfizer’s primary-care sales and consumer-marketing experience as potential commercial advantages.

Asked whether obesity medicines could eventually become available over the counter, Bourla said Pfizer has previously tried to move prescription products to over-the-counter status but regulators did not always agree. He said he does not expect a broad shift in regulators’ stance soon.

Oncology and inflammation programs

Bourla identified breast and prostate cancer as important areas for new products as Pfizer’s existing treatments IBRANCE and XTANDI go off patent. The first study of prostate cancer candidate mevrometostat is expected to read out early next year, with a second later in the year, he said.

If successful, mevrometostat could have greater potential than XTANDI because Pfizer would have rights to the product globally, Bourla said. Pfizer shares U.S. XTANDI sales with Astellas and does not receive sales outside the U.S., he added.

Bourla also highlighted Pfizer’s CDK4 breast cancer program, the multiple myeloma treatment ELREXFIO and lung cancer studies involving its PD-1/VEGF and antibody-drug conjugate portfolios.

In inflammation and immunology, Bourla said Pfizer is building a Phase 3 program for a trispecific treatment in atopic dermatitis, including a head-to-head study against DUPIXENT. He said the product could become a “mega blockbuster” if the program succeeds. For a separate STAT6 program, Pfizer is investigating drug-drug interactions before starting larger studies, he said.

Costs, AI and pricing

Bourla said Pfizer’s $7.2 billion in net savings would be realized by the end of the year and that the company has already announced another $1.5 billion in savings. He described artificial intelligence as a major tool for improving productivity and said its first impact would likely be in supporting functions.

He predicted Chinese companies would become Pfizer’s major competitors by 2030, citing their lower costs and faster pace. Pfizer’s goal, he said, is to “do more with less.”

On drug pricing, Bourla said the disparity between prices paid by U.S. patients and those in other developed countries is unsustainable. He said the issue would remain a concern for both major U.S. political parties.

About Pfizer (NYSE:PFE)

Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company's products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Pfizer Right Now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines